Navigation Links
MARC travel awards for the CYTO 2014/International Society for Advancement of Cytometry Meeting
Date:4/11/2014

Bethesda, MD FASEB MARC (Maximizing Access to Research Careers) Program has announced the travel award recipients for the CYTO 2014/ International Society for Advancement of Cytometry meeting in Ft. Lauderdale, FL from May 17-21, 2014. These awards are meant to promote the entry of students, post doctorates and scientists from underrepresented groups into the mainstream of the basic science community and to encourage the participation of young scientists at the CYTO 2014/ International Society for Advancement of Cytometry meeting. This year MARC conferred 2 awards totaling $3,700.

The FASEB MARC Program is funded by a grant from the National Institute of General Medical Sciences, National Institutes of Health. A primary goal of the MARC Program is to increase the number and competitiveness of underrepresented groups engaged in biomedical and behavioral research.

The following participants have been selected to receive a FASEB MARC Travel Award:

POSTER/ORAL PRESENTER (FASEB MARC PROGRAM)
Eric Prado, University of North Texas
Randall Williams, University of North Texas


'/>"/>

Contact: Kelly Husser
khusser@faseb.org
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1

Related biology news :

1. MARC travel awards announced for Immunology 2014, the American Association of Immunologists Annual Meeting
2. MARC travel awards announced for the 2014 Great Lakes Bioinformatics Conference
3. MARC travel awards announced for the American College of Sports Medicine 61st Annual Meeting
4. MARC travel awards announced for the American Physiological Society 2014 Professional Skills Training
5. MARC Travel Awards announced for the American Physiological Society Professional Skills Training
6. MARC Travel Awards announced for EB 2014
7. MARC Travel Awards announced for the Society for Developmental Biology NW Regional Meeting
8. MARC Travel Awards announced for the ASCI and AAP Joint Meeting
9. MARC Travel Awards announced for the 114th American Society for Microbiology General Meeting
10. 2014 ACMG Foundation/Signature Genomic Labs, PerkinElmer Inc. Travel Award winner
11. MARC Travel Awards announced for the 2014 GSA: 55th Annual Drosophila Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
(Date:5/28/2015)... 28, 2015 Industry analyst firm n-tech ... report titled "Markets for Self-Healing Materials: 2015-2022." According to ... and vascular systems, biomaterials, relevant shape memory materials ... $2.7 billion by 2020. The report ... of smart materials. Other recent n-tech reports have included ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... in which the circulating strains of influenza showed genetic ... flu shot was found to be effective in preventing ... vaccine also prevented illnesses but was less effective. , ... infection, a University of Michigan study found. , ...
... Muscle weakness and fiber deterioration seen in muscular dystrophy ... under study for their effects against cancer, a Burnham ... on the potential use of these drugs, called histone ... muscles, thereby countering the progression of the disease, in ...
... an innovative new project being developed by Central Queensland ... around the country could soon have access to rehabilitation ... than having to travel to special outpatient clinics. , ... on-line outpatient rehabilitation service for people who have had ...
Cached Biology News:Flu shot effective against drifted influenza, nasal spray vaccine less so 2Flu shot effective against drifted influenza, nasal spray vaccine less so 3Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy 2
(Date:5/29/2015)... NEW YORK , May 29, 2015 /PRNewswire/ ... a specialty pharmaceutical and medical device company focused ... of primary and metastatic liver cancers, announces that ... the treatment of uveal melanoma patients with hepatic ... Delivery System, were highlighted in an on-line abstract ...
(Date:5/29/2015)... 29, 2015  Caris Life Sciences ® , ... promise of precision medicine, today announced the presentation ... clinical utility of Caris Molecular Intelligence ® , ... helping to identify targeted treatment options for patients ... the studies, results of which are to be ...
(Date:5/29/2015)... WISCONSIN (PRWEB) May 29, 2015 Results ... virus talimogene laherparepvec and its ability to reduce the ... treatment have been published in the Journal of Clinical ... patients with stages IIIB, IIIC and IV melanoma, a ... of the study was to evaluate the safety and ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ... and Companies"  to their offering.  ... remains a challenge in management. With nearly ... the seven major markets of the world ...
Breaking Biology Technology:Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... ... ... var ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } ...
... 2010 The clinical trials program at UC San ... recognized educational programs of its kind in the world, ... Trials Administration in Latin America Certificate. Classes ... experience. Medica Sur, one of the most respected physician/research ...
... 30, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Biology Technology:Biovista Announces a Drug Repositioning Collaboration With Pfizer 2Biovista Announces a Drug Repositioning Collaboration With Pfizer 3Biovista Announces a Drug Repositioning Collaboration With Pfizer 4Biovista Announces a Drug Repositioning Collaboration With Pfizer 5Biovista Announces a Drug Repositioning Collaboration With Pfizer 6Biovista Announces a Drug Repositioning Collaboration With Pfizer 7Biovista Announces a Drug Repositioning Collaboration With Pfizer 8UC San Diego Offers New Certificate for Clinical Trials Administration in Latin America 2ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 2ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 3ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 4ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 5ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 6ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 7ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 8ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 9ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 10ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 11ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 12ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 13ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 14ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 15ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 16ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 17ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 18ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 19ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 20ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 21ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 22ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 23ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 24ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 25ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 26ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 27ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 28
...
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
Biology Products: